Emergency Use Authorizations (EUA) are a mechanism that allows the U.S. FDA to facilitate the availability of medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats, including emerging infectious diseases such as...
1 min read
Sponsors developing drugs or biologics intended to prevent, diagnose, or treat a rare disease or condition should consider applying for the Orphan Drug Designation (ODD) program with the FDA. The FDA’s Orphan Drug Designation program is meant to...
4 min read
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...
4 min read
Clinical and regulatory teams face increased pressure to drive uninterrupted progress across the clinical development pathway. These teams routinely benefit from the support of an external partner who can minimize the risks of failure and missed...
2 min read
Decentralized clinical trials (DCTs) are becoming increasingly popular to optimize patient engagement and retention. At the same time, making DCTs a successful reality for the most complex studies is considered difficult given the many logistical and...
5 min read
The Tufts CSDD Roundtable took place in November, and on behalf of Veristat, I was honored to participate in this invite-only program. It is part of our company’s DNA to stay ahead of the driving forces in the industry so that we can best serve as a...
2 min read
Did you know approximately 1 in 10 Americans are affected by a rare disease or condition according to the National Institutes of Health (NIH)? That’s 30 million people in the US, and similarly in the EU affected.Before 1983 in the US and 2000 in the EU,...
1 min read
GENESIS BIOMED recently interviewed Xavier Luria, former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), and now Veristat’s Vice President of Regulatory Affairs, Europe.
1 min read
The FDA and EMA offer expedited regulatory approval pathways to accelerate time-to-market for novel therapies intended to treat serious conditions and unmet medical needs. There are twelve special designations, many of which reduce clinical development...
4 min read
Effectively managing the publishing of documents required for a marketing application submission can help accelerate the time it takes to bring your product to market.